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Introduction
The combination of the medicinal substances in a single 
dosage form is a globally recognized practice. Due to the ad-
vantages of the fixed-dose combinations (FDCs) which have 
been shown over time, FDCs are widely applied in the treat-
ment of a large number of pathologies, such as cardiovascu-
lar [1, 2] and respiratory [3, 4], tuberculosis [5, 6], HIV [7], 
diabetes [8], pain management [9], infectious diseases [10]. 
Among the most important advantages are: (a) the improve-
ment of the response rate compared to monotherapy, based 
on different mechanisms of drug action in the combination; 
(b) reduced doses and toxicity; (c) achievement of the faster 
effect by FDC’s than monocomponent; (d) better complian-
ce by reducing the pill burden and adherence improvement; 
(e) low cost and saving of resources for the patients and the 
health system [11-13]. Most FDCs come in solid dosage for-
ms: tablets and capsules, containing two active ingredients, 
rarely three and more.
Hard capsules are used as a delivery system for FDCs due 
to the fact that they are inert and do not interact with drug’s 
components; they can have different sizes, including custo-
mized sizes and they are ideal for packaging of hygroscopic 
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Abstract
Background: UV-Vis spectrophotometry remains the most accessible spectral method with a high degree of sensitivity and information. The advantage 
of the method consists in its universality, the ability to combine with other methods, the minimum error, as well as its economic efficiency. The objective 
of this study was the  determination of some validation parameters for the spectrophotometric method of dosing piracetam and nicergoline in combined 
capsules.
Material and methods: Agilent 8453 UV-Vis spectrophotometer, reference standards of piracetam and nicergoline, 0.1 M HCl methanolic solution. 
Validation of the spectrophotometric method according to the requirements of the ICH guide “Q2R1: For analytical procedures and validation”. 
Results: Linearity was investigated on concentration ranges 5-40 µg / mL. The regression (R2) values  were 0.9998 for nicergoline and 0.998 for piracetam, 
respectively. The limit of detection was 1.737 µg / mL for nicergoline and 0.369 µg / mL for piracetam. Quantification limit values  were also calculated 
as 5.265 and 1.118 µg / mL for nicergoline and piracetam, accordingly. The results obtained showed that the developed spectrophotometric method is 
accurate, precise and robust, because the value of the relative standard deviation was less than 1.0%. 
Conclusions: The developed spectrophotometric method showed specificity, linearity, accuracy, precision and robustness, and can be applied on the 
concentration range between 80-120% of the nominal value of the content of nicergoline and piracetam in the preparation.
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substances; the production technology is not complicated; 
they are convenient for administration [14].
The development of combination drugs includes several 
specific steps, being a process with many challenges, related 
to the nature and properties of the active ingredients which 
can cause incompatibilities, different doses, different phar-
macokinetic properties and bioavailability etc. [15]. A major 
challenge in the development of FDCs is the development 
of analytical methods for the simultaneous determination of 
each component of the mixture. Researchers usually opt for 
physico-chemical methods, which offer the possibility of se-
parating the components, are accurate and sensitive. Nume-
rous factors, such as chemical structure, molecular weight, 
pKa values, UV absorption, concentration of active principle 
in the analyzed sample, solubility of compounds, are taken 
into account when selecting the method. Chromatographic 
methods, especially high pressure liquid chromatography 
(HPLC), are most often used for the analysis of combined 
products, the working techniques being complex and diffi-
cult to perform.
A very important step in the FDCs standardization is the 
development of the simple, accessible, fast and accurate me-
thods of analysis. UV-Vis spectrophotometry is one of the 
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alternatives that can be proposed and meets all the nomi-
nated requirements. It is based on the absorption of electro-
magnetic radiation by molecules of the substances. Therefo-
re, this method can be used successfully for the analysis of 
compounds with chromophore groups.
Hearing is one of the most important senses of human 
being, which is the source of sound, being an essential means 
of communication. Any difficulty in percepting the sound 
is defined as a hearing loss, pathology with various etiology 
and pathophysiological mechanisms. In neurosensory hypo-
acuzia, the difficulty of sound reset is determined by dys-
function in the inner ear [16]. Treatment of neurosensory 
hypoacuzia remains a serious problem. Corticosteroids are 
indicated as first-line medicines. At the same time, certain 
emphasis is placed on the advancement of the hemodyna-
mics in the region of the innear ear, the improvement of the 
metabolism, the blood rheology and the stimulation of the 
auditory analyzer. The medical treatment includes several 
types of medicines: vasodilators, nutrients, anti-inflamma-
tories, antioxidants. Medicines, in particular, vinpocetine, 
pentoxifylline, сеrеbrоlysin, рiraсеtam are given  in the first 
days рarеntеrally, then orally [17, 18]. The concomitant use 
of several medicines in treatment regimens for hearing loss 
justifies efforts to develop combined medicines, which wo-
uld solve several pharmacotherapeutic problems of this di-
sease. Thus, research was carried out at the Scientific Center 
for Drug Research (SCDR) in order to develop an original 
composition containing nicergoline, piracetam and Haw-
thorn dry extract in the one dosage form – capsules.
Nicergoline (fig. 1) is an analogue of ergot alkaloids, whi-
ch associates in the molecule a nucleus of hydrogenated ly-
sergic acid and nicotinic acid, belongs to the alpha-adrenoly-
tics group, possesses vasodilating action. Due to the presence 
of nicotinic acid in its structure, it manifests direct spasmo-
lytic myotropic action on the vessels muscles, increases their 
permeability for glucose. Nicergoline acts predominantly on 
the cerebral vessels and lower and upper limbs, improves ce-
rebral, pulmonary and renal blood circulation [19].
Piracetam (fig. 1) is a cyclized derivative of gamma-ami-
nobutyric acid, with nootropic action, intensifies energy and 
plastic processes in the brain, has the ability to restore the 
structure of cell membranes, the three-dimensional structu-
re of membrane and transmembrane proteins, with the reco-
very of their functionality [20]. 
1 2 
3 4 
Fig. 1. the chemical structures of nicergoline (left) [21] and 
piracetam (right) [22]
Data from the literature provide information on several 
methods applied in bulk nicergoline analysis, in one-compo-
nent forms or various combinations: HPLC [23], spectrofluo-
rimetry [24, 25], spectrophotometry [26]. Chromatographic 
[27-29] and spectral [30, 31] methods are also reported for 
piracetam. It should be noted that the simultaneous determi-
nation of these two substances has not been reported, since 
they are associated for the first time in the same pharmace-
utical form.
The purpose of this study was to develop and validate a 
simple, accurate and reproducible UV-Vis spectrophotome-
tric technique to analyze nicergoline in combination with 
piracetam in capsules.
Material and methods
The experimental researches were carried out at the Lab-
oratory of elaboration, analysis, standardization and control 
of medicines (LEASCM) of the SCDR within Nicolae Tes-
temitanu State University of Medicine and Pharmacy.
The elaboration of the assay method of combined cap-
sules was performed based on the requirements of the ICH 
guideline “Q2R1: For analytical and validation procedures” 
[32].
Three experimental series of laboratory-prepared oper-
culated capsules containing nicergoline, piracetam, Haw-
thorn dry extract and excipients were used in the studies. 
Apparatus
The Agilent Technologies 8453 Spectrophotometer 
equipped with 10 mm matched quartz cells was used.
Substances, solvents and reagents
Reference standards of nicergoline and piracetam (Sigma 
Aldrich), methanol (MeOH, Sigma Aldrich), hydrochloric 
acid (HCl) 0,1 M were used.
Preparation of the standard solutions
0.05 g of standard piraсetam was transferred into a 25 mL 
volumetric flask, was dissolved in 0.1 M HCl methanol solu-
tion and then adjusted up to the mark with the same diluent. 
1.2 mL of the obtained solution was transferred into a 25 mL 
volumetric flask and adjusted up to the mark with the same 
diluent (dil.1). After that, 2.5 ml of obtained solution was 
diluted to 10 mL with the same diluent (dil.2). 
0.005 g of standard nicergoline was transferred into a 25 
mL volumetric flask, dissolved in 0.1 M HCl methanol so-
lution and adjusted up to the mark with the same diluent. 
Then, 5.0 mL of obtained solution was transferred into a 25 
mL volumetric flask and volume was adjusted up to the mark 
with the same diluent (dil.1). After that, 2.5 ml of obtained 
solution was diluted to 10 mL with the same diluent (dil.2).
Preparation of the sample solutions
A content weight of one capsule was taken into a 50 mL 
volumetric flask, then 40 mL of 0.1 M HСl methanol soluti-
on was added and shaken well until it dissolved. After that, 
the obtained solution was filtered and made up to the mark 
with the same diluent (stock solution). For the analysis of pi-
racetam, 0.6 mL of stock solution was withdrawn and taken 
into a 50 mL volumetric flask. The volume was adjusted up 
to mark with the same diluent (dil.1). Then, 5 mL of obtained 
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solution was diluted to 10 mL with the same diluent (dil.2). 
For the analysis of nicergoline, 10.0 mL of stock solution was 
withdrawn and taken into a 25 mL volumetric flask. The vo-
lume was adjusted with the same diluent up to mark (dil.1). 
Then, 5 mL of obtained solution was diluted to 10 mL with 
the same diluent (dil.2). 
Preparation of placebo solutions
Accurately weighed Hawthorn dry extract and excipients 
were calculated for one capsule and were taken into a 50 mL 
volumetric flask. Then, 40 mL of 0.1 M HСl methanol solu-
tion was added and shaken well until it dissolved. After that, 
the obtained solution was filtered and made up to the mark 
with the same diluent (placebo solution). For the analysis of 
piracetam, 0.6 mL of placebo solution was withdrawn and ta-
ken into a 50 mL volumetric flask. The volume was adjusted 
up to mark with the same diluent (dil.1). Then, 5 mL of ob-
tained solution was diluted to 10 mL with the same diluent 
(dil.2). For the analysis of nicergoline, 10.0 mL of placebo 
solution was withdrawn and taken into a 25 mL volumetric 
flask. The volume was adjusted up to mark with the same 
diluent (dil.1). Then, 5 mL of obtained solution was diluted 
to 10 mL with the same diluent (dil.2). 
Quantitative determination
The absorbance of standard and sample solutions was 
measured using 10 mm matched quartz cells and 0.1 M HСl 
methanol solution as reference solution.
The quantitative content of nicergoline and piracetam in 
capsules was determined by using Eq. (1):
              Aan*mst * Wan*P X, g = -----------------------, in which:                                 (1)
               Ast*man * Wst 
Aan – absorbance of the sample solutions;
Ast – absorbance of the standard solutions;
Man – mass of the sample substance, g; 
mst – mass of the standard substance, g; 
P – average content mass of one capsule;
Wst and Wan – the volumes of dilution for standard and 
sample solutions respectively.
Validation of the method
According to the ICH guide the method was validated 
for parameters, such as  linearity, accuracy, precision, sensi-
tivity (LOQ and LOD) and robustness, selectivity, solution 
stability [32].
The linearity of the spectrophotometric method of assay 
of piracetam and nicergoline was investigated in the con-
centration range from 5 – 40 μg / mL. Thus, standard stock 
solutions of substances were prepared: 5 samples with dif-
ferent concentrations of piracetam and nicergoline of 5, 10, 
24, 30, 40 μg / mL and 5, 10, 15, 20, 30 μg / mL, respective-
ly. The determinations were performed in triplicate, being 
constructed the calibration curve (fig. 2). Linear regression 
analysis was used to evaluate the linearity of the calibration 
curve using the least squares method.
The selectivity of the spectrophotometric method of assay 
of piracetam and nicergoline was investigated by measuring 
the absorbance of the placebo solutions at the spectrophoto-
meter using the 10 mm matched quartz cells in the wavelen-
gth range 200 – 350 nm. 0.1 M HСl methanol solution was 
used as the reference solution.
Determination of the accuracy of the method was prepa-
red using three samples consisting of nicergoline, piracetam 
and a mixture of excipients in 0.1 M HСl methanol solution 
at concentration levels of  80 – 120% of the stated amount, 
with 3 replicates for each concentration. The percentage re-
covery of the amount of substance and % RSD were calcu-
lated for each of the replicate samples (tab. 1).
The nicergoline and piracetam concentrations were de-
termined using the calibration curve, and  the percentage of 
regression has been established by using Eq. (2).
           R = [(Ct – Cp)/Ca]*100%, where:                                                                  (2)
R – recovery, %;
Ct – concentration of the sample with the addition, µg/mL;
Cp – sample concentration without addition, µg/mL;
Ca – concentration of the standard with the addition, µg/mL.
Determination of precision of the method was performed 
by evaluating repeatability and intermediate precision [33]. 
Repeatability was determined using six samples of capsules, 
which were analyzed on the same day and under the same 
conditions. Intermediate precision was determined using six 
samples of capsules, which were analyzed in different days 
over the period of a week by different analysts (tab. 2). The 
concentration of nicergoline and piracetam from capsules 
was determined.
The sensitivity of the method was investigated by deter-
mining the limit of detection (LOD) and limit of quantifica-
tion (LOQ) by analyzing the substance solutions and mea-
suring the signal-to-noise ratio. LOD is the concentration, 
which is due to the signal/noise ratio of about 3:1, while 
LOQ is the concentration that gives a signal/noise ratio of 
about 10:1 with RSD values (n = 3) less than 10%.
The robustness of the method was investigated by varying 
the maximum absorption wavelength of nicergoline and pi-
racetam with ±2 nm [32]. The determinations were repeated 
3 times at each wavelength (tab. 3).
The stability of standard and sample solutions was deter-
mined by analyzing them immediately after preparation and 
after 24 hours at room temperature (25°C). Three determi-
nations were performed, the absorbance was evaluated, the 
concentrations of analyte in the samples (relative to a freshly 
prepared reference solution) and the % RSD were calculated 
(tab. 4).
Statistical analysis
Statistical analysis was carried out by using the Statistical 
Package for the Social Sciences (IBM SPSS Statistics) 10.5 
software.
Results and discussion
The piracetam and nicergoline standard solutions 
showed absorption maxima at 205 nm and 287 nm, respec-
tively. The same maxima were detected on the spectrum of 
the sample solution. The spectrum of the placebo solution 
showed a very low absorption at 272 nm (fig. 2).
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The validation of the method was carried out in accor-
dance with the ICH Guide ”Q2R1: For Analytical Procedu-
res and Validation” [32]. 
The linearity of the UV-Vis spectrophotometric method 
was determined in the concentration range of 5 – 40 μg/mL 
Fig. 2. Absorption spectra of standard piracetam (1) and nicergoline (2), sample (3) 
and placebo (4) solutions in 0.1 M HСl methanol solution
Fig. 3. Absorption spectra of piracetam (left) and nicergoline (right)
standard solutions for linearity
of piracetam and 5 – 30 μg/mL of nicergoline. Based on the 
obtained results, the calibration curve was drawn and the 
equation of linear regression was obtained (fig. 3 and 4).
The obtained results showed a linear regression of the 
method in the concentration range between 5 – 40 μg/mL of 
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Accuracy is expressed as the percentage of recovered ana-
lytes compared to actual values (tab. 1). The admissibility 
condition is at least 99% [32]. 
The developed UV-Vis spectrophotometric method for 
the assay of nicergoline and piracetam  from combined cap-
sules, is accurate, with an average recovery value ranging 
from 99.8% to 101.8%.  RSD values were between 0.11 – 
0.69%, as indicated in tab. 1.
Precision is generally expressed by standard deviation 
and standard relative deviation. As a result of studies the ave-
rage values of substance concentrations were calculated after 
6 determinations for each 3 capsule series (tab. 2).
The values of LOD calculated in accordance with the ICH 
guide were 1.737 µg / mL for nicergoline and 0.369 µg / mL 
for piracetam [32].
The values of LOQ calculated in accordance with the ICH 
guide were also calculated as 5.265 and 1.118 µg / mL for 
nicergoline and piracetam, respectively [32].
The method is selective, as placebo solution showed a 
very low absorption at the wavelength (272 nm) different 
from the absorption peaks of nicergoline and piracetam. 
Also, Hawthorn dry extract and excipients did not influence 
the results of the determinations.
Fig. 4. Calibration curves of standard solutions of piracetam (left) and nicergoline (right) (n = 3 determinations)
 
table 1. Recovery as a condition of admissibility
Nr.
The amount of Ciprofloxacin hydrochloride taken 
into work





(%) (mg/mL) (mg/mL) (%) (%)
N P N P N P N P N/P
1 80 80 8.0 8.0 7.94 8.05 99.21 101.78 0.69/0.53
2 100 100 10.0 10.0 10.04 9.99 100.73 99.80 0.19/0.11
3 120 120 12.0 12.0 11.99 12.01 99.95 100.15 0.23/0.54
Note: N – Nicergoline, P – Piracetam, RSD – Relative standard deviation.
table 2. Results of the repeatability determination and intermediate precision for piracetam and nicergoline in 
combinated capsules
Parameters Repeatability: C, g Intermediate precision: C, g
Substances P N P N
Series S 01 S 02 S 03 S 01 S 02 S 03 S 01 S 02 S 03 S 01 S 02 S 03
1 0.2010 0.2001 0.2001 0.0046 0.0046 0.0046 0.2000 0.1997 0.2000 0.0046 0.0046 0.0046
2 0.2005 0.2001 0.2003 0.0045 0.0045 0.0046 0.2003 0.1997 0.1999 0.0045 0.0046 0.0046
3 0.2006 0.2004 0.2001 0.0046 0.0046 0.0045 0.2013 0.1999 0.2001 0.0045 0.0046 0.0045
4 0.2004 0.2006 0.2003 0.0046 0.0046 0.0045 0.1997 0.1994 0.1997 0.0045 0.0045 0.0045
5 0.1999 0.2004 0.2003 0.0045 0.0045 0.0045 0.1997 0.1992 0.2001 0.0045 0.0045 0.0045
6 0.1999 0.2001 0.2001 0.0046 0.0046 0.0046 0.2000 0.1999 0.1997 0.0045 0.0045 0.0045
Average 0.2004 0.2003 0.2003 0.0046 0.0046 0.0046 0.2002 0.1997 0.1999 0.0045 0.0046 0.0046
RSD, % 0.2122 0.1049 0.0703 0.5897 0.5160 0.8382 0.2940 0.1450 0.0940 0.7156 0.9528 0.7189
Note: N – Nicergoline, P – Piracetam, RSD – Relative standard deviation.
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The results of the determinations showed that the meth-
od is accurate within acceptable limits, RSD values were ≤ 
2% (between 0.07 and 0.95), so, the developed UV-Vis spec-
trophotometric method is precise.
Robustness is usually fixed to determine, if the results of 
the determinations will not be influenced by some insigni-
ficant variations in the established parameters, respectively, 
the validity of the analytical process will be maintained con-
stant. The robustness of the developed method was determi-
ned by the variation of wavelengths ±2 nm (tab. 3).
The results obtained showed that the developed spectro-
photometric method is robust, the relative standard devia-
tion is less than 1.0%.
The results of the short-term stability were within the 
acceptance range. Also, the results showed that the samples 
were stable at room temperature for 24 hours. Acceptance 
criteria is: RSD ≤ 2% [34] (tab. 4).
table 4. Results of the short-term stability determined 
by the proposed method (n=6)
Nr.
Concentration of piracetam and nicergoline from 
capsules, g
Declared Found
P N P N
1 0.2000 0.0045 0.2016 0.0046
2 0.2000 0.0045 0.2014 0.0045
3 0.2000 0.0045 0.2011 0.0046
4 0.2000 0.0045 0.2001 0.0046
5 0.2000 0.0045 0.1998 0.0045
6 0.2000 0.0045 0.1989 0.0046
Average 0.2000 0.0045 0.2005 0.0046
RSD, % 0.2016 0.5897
Note: N – N icergoline; P – Piracetam; RSD – Relative standard devia-
tion
Conclusions
For the first time, the UV-Vis spectrophotometric meth-
od of concomitant dosing of piracetam and nicergoline in 
combined capsules was developed and validated. The pro-
posed work technique is simple, accessible, fast, accurate, 
sensitive and reproductive. The developed spectrophotomet-
ric method serves as an alternative to the chromatographic 
method (HPLC), and can be included in the quality speci-
fication for capsules combined with piracetam, nicergoline 
and Hawthorn dry extract.
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